skip to main content


Title: Colloidal Gold Nanoparticles Induce Apoptosis in MCF-7 Human Breast Adenocarcinoma Cells
Nanoparticles have been widely used as remedies for disorders for a long time. They are 10-9 m specks of substances that can be found both naturally and synthesized in the laboratory with metal and nonmetal materials. In this study, gold nanoparticles (AuNPs) were synthesized using the citrate reduction method, and the 35 nm size of the nanoparticles was determined using a UV-Vis Spectrophotometer at 525 nm wavelength. The synthesized nanoparticles were further studied on MCF-7 breast cancer cells to understand how various genes are expressed in the induction of apoptosis in signal transduction pathways. The results obtained from the anticancer activity of the gold nanoparticles showed approximately 90% inhibition of cell growth after 72 hours of treatment. Western blot analysis demonstrated the downregulation of p44/42 MAPK (ERK1/2) protein due to gold nanoparticle treatment. Moreover, reverse transcription-polymerase chain reaction (RT-PCR) analysis of apoptotic genes revealed the upregulation of the p53 tumor suppressor gene, Bax, and caspase-9. The results assembled from this study further indicates that p44/42 MAPK, p53, caspase 9 and Bax play a major role in the mechanism of apoptosis in the MCF-7 breast cancer cells.  more » « less
Award ID(s):
1719607
NSF-PAR ID:
10143041
Author(s) / Creator(s):
; ;
Date Published:
Journal Name:
Nano research applications
Volume:
5
Issue:
2.5
ISSN:
2471-9838
Page Range / eLocation ID:
1-6
Format(s):
Medium: X
Sponsoring Org:
National Science Foundation
More Like this
  1. Curcumin is a derivative of the turmeric spice, which is a yellow-pigmented root crop with a resilient sheath and bright orange flesh. It is originally known to be utilized in Asian dishes but, has been discovered to have antioxidant, anti-inflammatory, antiviral, antibacterial and anticancer characteristics. Different researchers have established great possibilities of curcumin's ability to prohibit the growth of cancer cells especially, because of its potentiality to differentiate between normal and cancerous cells. Research questions include understanding the effects of curcumin on the MCF-7 breast cancer cells with regards to the biomolecules of the cells. The results indicated that after attachment of cells for 48 hours, the concentration of curcumin at 15 µM showed more than 90% inhibition of cells within 24 hours. The analysis was carried out on the viability of the cells, western blotting and reverse transcriptase-polymerase chain reaction. Western blot analysis of signaling proteins from curcumin-treated cells showed that the expression level of phosphorylated protein p44/42 in the MAP kinase pathway was significantly decreased and the apoptotic marker cleaved caspase 3 was increased as compared to the curcumin-untreated control cells. Moreover, RT-PCR analysis of the reference genes in the apoptotic pathway (p53, caspase 9, BCL-2 and Bax) demonstrated the upregulation of p53, Bax and caspase 9 genes. The results assembled from this present study suggested that curcumin inhibited the growth and induced caspase-mediated apoptosis of MCF-7 cells via the MAPK signaling pathway. Therefore, breast cancer treatment with curcumin seems to be a promising remedial path in near future. 
    more » « less
  2. Three new organotin( iv ) carboxylate compounds were synthesized and structurally characterized by elemental analysis and FT-IR and multinuclear NMR ( 1 H, 13 C, 119 Sn) spectroscopy. Single X-ray crystallography reveals that compound C2 has a monoclinic crystal system with space group P 2 1 / c having distorted bipyramidal geometry defined by C 3 SnO 2 . The synthesized compounds were screened for drug-DNA interactions via UV-Vis spectroscopy and cyclic voltammetry showing good activity with high binding constants. Theoretical investigations also support the reactivity of the compounds as depicted from natural bond orbital (NBO) analysis using Gaussian 09. Synthesized compounds were initially evaluated on two cancer (HeLa and MCF-7) cell lines and cytotoxicity to normal cells was evaluated using a non-cancerous (BHK-21) cell line. All the compounds were found to be active, with IC 50 values less than that of the standard drug i.e. cisplatin. The cytotoxic effect of the most potent compound C2 was confirmed by LDH cytotoxicity assay and fluorescence imaging after PI staining. Apoptotic features in compound C2 treated cancer cells were visualized after DAPI staining while regulation of apoptosis was observed by reactive oxygen species generation, binding of C2 with DNA, a change in mitochondrial membrane potential and expression of activated caspase-9 and caspase-3 in cancer cells. Results are indicative of activation of the intrinsic pathway of apoptosis in C2 treated cancer cells. 
    more » « less
  3. Three triorganotin (IV) cyclopentane carboxylates were synthesized and structurally characterized by in solid state by Fourier‐transform infrared spectroscopy and single crystal diffraction, and in solution by NMR (1H,13C, and119Sn) spectroscopy. The complexes were tested for their anticancer activity against MCF‐7 and HeLa cells along with normal BHK‐21 cells. As revealed by MTT assay, complex2was identified as the most potent derivative with an IC50value of 2.59 and 0.051 μM against HeLa and MCF‐7 cells, respectively. The results were compared with cisplatin as reference drug. Fluorescent microscopic studies using 4′,6‐diamidino‐2‐phenylindole (DAPI) and propidium iodide (PI) staining confirmed the occurrence of apoptosis in HeLa cells treated with the most active complex2. The complex2also triggered the release of lactate dehydrogenase (LDH) in treated HeLa and MCF‐7 cells whereas a luminescence assay displayed a remarkable increase in the activity of caspase‐9 and ‐3. Moreover, flow cytometric results revealed that complex2caused G0/G1 arrest in the treated HeLa cells. The complexes were further screened for DNA binding studies through UV‐vis spectroscopy and cyclic voltammetry. The high activity of complex2was attributed to its higher Lewis acidity as indicated by natural bond orbital (NBO) analysis. Theoretical modelling and molecular docking studies were also conducted to study the reactivity of complexes againstVEGFR 2 Kinase.

     
    more » « less
  4. ABSTRACT

    EseN is anEdwardsiella ictaluritype III secretion system effector with phosphothreonine lyase activity. In this work, we demonstrate that EseN inactivates p38 and c-Jun-N-terminal kinase (JNK) in infected head-kidney-derived macrophages (HKDMs). We have previously reported inactivation of extracellular-regulated kinase 1/2 (ERK1/2). Also, for the first time, we demonstrated that EseN is involved in the inactivation of 3-phosphoinositide-dependent kinase 1 (PDK1), which has not been previously demonstrated for any of the EseN homologs in other species. We also found that EseN significantly affected mRNA expression ofIL-10, pro-apoptoticbaxa, andp53, but had no significant effect on anti-apoptoticbcl2or pro-apoptotic apoptotic peptidase activating factor 1. EseN is also involved in the inhibition of caspase-8 and caspase-3/7 but does not affect caspase-9 activity. Repression of apoptosis was further confirmed with flow cytometry using Alexa Fluor 647-labeled annexin V and propidium iodide. In addition, we found that theE. ictaluriT3SS is essential for the inhibition of IL-1β maturation, but EseN is not involved in this process. EseN did not affect cell pyroptosis, as indicated by the lack of EseN impact on the release of lactate dehydrogenase from infected HKDM. The transmission electron microscopy data also indicate that HKDM infected with WT or aneseNmutant died by apoptosis, while HKDM infected with the T3SS mutant more likely died by pyroptosis. Collectively, our results indicate thatE. ictaluriEseN is involved in inactivation of ERK1/2, p38, JNK, and PDK1 signaling pathways that lead to modulation of cell death among infected HKDMs.

    IMPORTANCE

    This work has global significance in the catfish industry, which provides food for increasing global populations.E. ictaluriis a leading cause of disease loss, and EseN is an important player inE. ictalurivirulence. TheE. ictaluriT3SS effector EseN plays an essential role in establishing infection, but the specific role EseN plays is not well characterized. EseN belongs to a family of phosphothreonine lyase effectors that specifically target host mitogen activated protein kinase (MAPK) pathways important in regulating host responses to infection. No phosphothreonine lyase equivalents are known in eukaryotes, making this family of effectors an attractive target for indirect narrow-spectrum antibiotics. Targeting of major vault protein and PDK1 kinase by EseN has not been reported in EseN homologs in other pathogens and may indicate unique functions ofE. ictaluriEseN. EseN targeting of PDK1 is particularly interesting in that it is linked to an extraordinarily diverse group of cellular functions.

     
    more » « less
  5. Abstract

    Peptide‐based nanomaterials are increasingly gaining popularity due to their specificity, biocompatibility, and biodegradability. In this work, a new multi‐layered peptide‐based biocomposite for targeting MCF‐7 breast cancer cells is developed. The amphipathic Fluorenylmethyloxycarbonyl (Fmoc)‐Leu‐Ser peptide is synthesized, which is conjugated to a tumor‐targeting peptide sequence Gly‐Cys‐Gly‐Asn‐Ser to form Fmoc‐L‐S‐G‐C‐G‐N‐S (FLS) assemblies. To the FLS assemblies, gold nanorods are then attached to develop drug delivery vehicles (DDVs). The DDVs are entrapped with the anti‐cancer drug fulvestrant. Entrapment efficiency is found to be 50.6%. Release studies indicate that irradiating the gold nanorod bound DDVs at NIR wavelength (785 nm) increases drug release by fourfold compared to assemblies that are not irradiated. These results also show higher cytotoxicity and lower cell invasion due to photo‐triggered drug release. Furthermore, distinct actin cytoskeletal changes are observed. Such novel peptide‐based gold nanorod bound DDVs demonstrate potential in dual targeting of MCF‐7 breast cancer cells.

     
    more » « less